Atlantic Research Group


Case Study:

A Life-Saving Drug’s Race to America

Cinryze Case StudyTransforming the lives of people living with Hereditary Angioedema (HAE) by empowering CRAs

 

For people living with hereditary angioedema (HAE), a devastating rare disease that causes severe swelling in many parts of the body, there has been no treatment available in America. Until now.

 

A small biotech set out to bring Cinryze — an HAE drug previously approved in Europe — to America. Initially, however, the trial did not go as planned.

 

The Problem:
The first large CRO that managed the trial had 100% CRA turnover, resulting in damaged relationships with key sites. Recruitment stalled.

 

The ARG Solution:
ARG deployed experienced and strategic CRAs. ARG’s approach empowered CRAs on the frontlines of clinical sites to proactively solve novel problems, establish meaningful face-to-face relationships with study coordinators, and spend extra time answering questions. The ARG difference accelerated recruitment and guaranteed the success of this pivotal study — with a 0% CRA turnover rate.

Please fill out the form below to access the case study.

Verification Code

Please enter the letters as they are shown in the image above.
Letters are not case-sensitive.